Denosumab delays the time to first skeletal-related event in patients with myeloma

Conferences, MyelomaLeave a comment

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab (XGEVA) had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p<0.001). The study met its primary endpoint, demonstrating denosumab is non-inferior to zoledronic acid in delaying the time to first on-study…

Psychological intervention lowers survivors’ fear of cancer recurrence

ConferencesLeave a comment

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) June, 2, 2017 CHICAGO – About 50% of all cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life, according to a study presented during the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. Yet, interventions to alleviate this…

MPE Advocate Development Programme (ADP)

MPELeave a comment

The MPE Advocate Development Programme (ADP) is a training programme directed to MPE members with the aim to provide them with the skills and knowledge that any myeloma patient advocate should have regarding the drug development process. The main goal of MPE is to put medicines research into a myeloma context and create a tailored training programme for the myeloma community.

Mayo Clinic researchers identify therapy that shrinks tumors in patients with myeloma

MyelomaLeave a comment

PHOENIX – Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by myeloma. The findings are published in Nature Medicine. Myeloma is a blood cancer that affects plasma cells – white blood cells that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body,…

In Memoriam of Mika Peltovaara

MPELeave a comment

It is with great sadness that we share with you that our friend, colleague and Board member Mika Peltovaara (23 Dec 1965 – 21 Febr 2017) passed away in the morning of the 21th of February 2017. Mika was board member of Myeloma Patients Europe since 2014. He was a very experienced, long-serving patient advocate for the Finnish Cancer Patient Association, with a special interest in possibilities of social media and new technologies in connecting…

Most of the contracts between pharma and patient organisations are difficult to understand and contain unreasonable clauses

MPELeave a comment

The contracts provided to patient advocates are often too long, difficult to understand for patient advocates, contain ambiguous clauses, contain terms that are in conflict with the very nature of patient advocacy, or even put the signing patient advocate at legal risk. That is what a survey run by the pan-European patient advocacy network Myeloma Patients Europe (MPE), and further supported by a network of 21 pan-European cancer patient advocacy organisations (WECAN) from other disease…